Serum Interleukin-17 Level In Patients Research Articles

Serum Interleukin-17 Level in Patients with Rheumatoid Arthritis and its Relation to Disease Activity

Background: Rheumatoid arthritis (RA) is a disease of progressive inflammatory autoimmune nature with articular and systemic effects. Its definite cause is unknown, but environmental and genetic factors are contributory. Aim of the Work: The aim of this study was to estimate the serum level of IL-17 in cases with RA and investigate its relation with disease activity among Egyptian population. Subjects and Methods: This study included 20 RA cases and 20 healthy control subjects. All cases were subjected to full history taking, thorough clinical examination, laboratory investigations including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-cyclic-citrullinated peptide (anti-CCP) antibodies and rheumatoid factor (RF). Enzyme linked immunosorbent assay was used to measure serum IL-17 level. Disease activity score-28 (DAS-28) was assessed. Results: The mean disease duration of the cases was 5.95±2.52 years (2–10years). DAS-28 ranged between 2.4 and 6.1 with a mean of 3.87±1.32. Serum IL-17 level was higher in the RA group (226.6±215.6 pg/ml) than the control group (48.17±54.9pg/ml) with p-value of 98.2 pg/ml had sensitivity and specificity of 81.2% and 75%, respectively. Conclusion: Serum IL-17 level was significantly increased in cases with RA compared to healthy controls. Its significant correlation with DAS-28 suggested that serum IL-17 level could be an important marker of disease activity in RA.

Serum interleukin-17 level in patients with ankylosing spondylitis and its relation with disease activity

Objective The aim of this study is to measure the level of interleukin-17 (IL-17) in the serum of patients with ankylosing spondylitis (AS) and correlating it with disease activity. Background AS is a chronic inflammatory disease that affects axial joints, characterized by a diffuse stiffness, with the advanced stage producing a rigid spine from the occiput to the sacrum. IL-17 may play a role in the pathogenesis, activity, and clinical manifestations of AS. IL-17 is produced by T helper 17 cells. Methods Fifty patients with AS (male:female 48:2) and 20 age-matched healthy male volunteers as controls were included in this study. Patients were diagnosed as having AS according to Assessment of SpondyloArthritis International Society criteria. All were subjected to demographic data, clinical examination, and laboratory investigations including serum level of IL-17A by enzyme-linked immunosorbent assay. The results were correlated with disease activity, which was assessed by Bath Ankylosing Spondylitis Disease Activity Index and Ankylosing Spondylitis Disease Activity Score. Results In our study, the serum levels of IL-17A in patients were significantly higher than those of the healthy controls (P Conclusion Serum IL-17A levels of patients with AS were significantly higher than healthy controls, and it was positively correlated with disease activity.

Study of Serum Interleukin-17 Levels in Patients with Chronic Periodontitis and Coronary Heart Disease

Study of Serum Interleukin-17 Levels in Patients with Chronic Periodontitis and Coronary Heart Disease

Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma

The promotion of tumor growth is due to a combination of several mechanisms, including angiogenesis and the abundance of cell-derived inflammatory cytokines. The aim of this study was to investigate the serum levels of interleukin 17 (IL-17) and the expression of p53 and Vascular Endothelial Growth Factor (VEGF), in order to determine the relationship between these markers and serum IL-17 levels in patients with colorectal carcinoma. Serum levels of the proinflammatory cytokine IL-17 in patients with colorectal carcinoma (CRC) (n=40) and in a healthy group (n=37) were analysed by ELISA. Surgically resected specimens of 59 colorectal carcinomas were studied by immunohistochemical staining for VEGF and p53. Analyses by ELISA showed significantly higher IL-17 serum levels in patients with colorectal carcinoma than in control subjects (IL-17; mean 128.52+/-47.62 pg/ml vs. mean 101.91+/-22.46 pg/ml; p=0.022). We also found an inverse correlation between p53 expression and the level of IL-17 in the serum of patients with CRC. In fact, the serum concentration of IL-17 was significantly higher in patients who did not express p53 (p=0.023). There was no significant correlation between the expression of p53 and VEGF. However, concomitant expression of VEGF and p53 showed a significant correlation with the histological and nuclear grade of the carcinoma. The data presented in our study indicate that IL-17 might act as a valuable tumor marker in patients with CRC and that combined analysis of p53 and VEGF expression might provide additional information about tumor features.

Increased serum interleukin 17 in patients with systemic lupus erythematosus

Interleukin 17 (IL-17) is a Th17 cytokine associated with inflammation, autoimmunity and defense against some bacteria, it has been implicated in many chronic autoimmune diseases including psoriasis, multiple sclerosis and systemic sclerosis. However, whether IL-17 plays a role in the pathogenesis of systemic lupus erythematosus (SLE) remains unclear. In the present study, we aimed to investigate the serum IL-17 level in patients with SLE and it's associations with disease manifestations and activity. Fifty-seven patients with SLE and 30 healthy volunteers were recruited. Serum IL-17 levels were examined by enzyme linked immunosorbent assay (ELISA). Statistic analyzes were performed by SPSS 10.01. Results show that serum IL-17 levels were significantly elevated in SLE patients as compared with normal controls. Nevertheless, no associations of serum IL-17 level with clinical and laboratory parameters were found; no significant difference regarding serum IL-17 level between SLE patients with nephritis and those without nephritis was found; no significant difference was found between Less active SLE and More active SLE; Correlation analysis between serum IL-17 levels and SLEDAI showed no association. Taken together, our results indicate increased serum IL-17 levels in SLE patients, suggesting that this cytokine may trigger the inflammatory process in SLE. However, no associations of serum IL-17 level with disease manifestations were found. Therefore, further studies are required to confirm this preliminary data.